ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017
(Thomson Reuters ONE) -
Chief Development Officer Dr. Johanne Kaplan to chair session
ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC):
16-20 JULY, 2017 LONDON, ENGLAND
TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 5, 2017- ProMIS
Neurosciences, Inc., a biotechnology company focused on the discovery and
development of precision treatments for neurodegenerative diseases, today
announced the Company will present preclinical data for its lead product
candidate, PMN310, at the Alzheimer's Association International Conference
(AAIC) to be held in London on July 16-20.
Johanne Kaplan, Ph.D., ProMIS Chief Development Officer, will present the data
and chair the associated session, entitled Preclinical: Basic Therapeutics -
Targeting Amyloid or Tau.
The presentation by Kaplan (et al.), entitled Targeting of toxic amyloid-beta
oligomer species by monoclonal antibody PMN310: Precision drug design for
Alzheimer's disease describes the use of ProMIS' proprietary discovery engine
for the identification and generation of monoclonal antibodies against specific
targets on toxic forms of amyloid beta (A-beta), a recognized root cause of
Alzheimer's.
Commenting on the presentation, Dr. Kaplan stated, "Antibody PMN310 was selected
as our lead product for development on the basis of its ability to selectively
target and neutralize toxic A-beta oligomers with no significant off-target
binding to A-beta monomers or fibrils. These characteristics distinguish PMN310
from other A-beta antibodies currently undergoing clinical trials, and are
designed to achieve optimal efficacy and safety".
ProMIS is very pleased to contribute to this year's AAIC, the world's largest
forum where international investigators, clinicians and care providers gather to
share the latest study results, theories and discoveries that will help bring
the world closer to breakthroughs in dementia science.
The session and presentation details are as follows:
Session: Preclinical: Basic Therapeutics - Targeting Amyloid or Tau
Presentation: Targeting of toxic amyloid-beta oligomer species by monoclonal
antibody PMN310: Precision drug design for Alzheimer's disease
Date/Time of session: 4:15-5:45 PM, July 17, 2017
Location: ExCel, London, Royal Victoria Dock
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO),
headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts.
The mission of ProMIS is to discover and develop precision medicine therapeutics
for effective treatment of neurodegenerative diseases, in particular Alzheimer's
disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS((TM)) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic
against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843
David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310
cbealamaro(at)streetwisereports.com
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.07.2017 - 15:01 Uhr
Sprache: Deutsch
News-ID 551140
Anzahl Zeichen: 6384
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 308 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
